Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients

Withdrawn

• Conditions: Meningioma; Glioma

• Registration Number: NCT00985036
• Lead Sponsor: Marquette General Health System

Brief Summary

Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:

1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?

2. Is the VEGF level an indicator of the response to treatment?

3. Does the VEGF level correlate with tumor histology and behavior?

4. Is there a relationship between VEGF level and outcome?

Detailed Description

Not available

Study Timeline

• Study Start: 2009-09
• Study First Submitted: 2009-09-25
• Study First Submitted QC: 2009-09-25
• Study First Posted: 2009-09-28
• Primary Completion: 2011-09
• Study Completion: 2012-01
• Status Verified: 2012-04
• Last Update Submitted: 2012-04-20
• Last Update Posted: 2012-04-24

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• any patient presenting with glioma or meningioma

Exclusion Criteria

• a different type of brain tumor

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine if VEGF levels correlate with tumor progression or recurrence	every one to three months

Secondary Outcome Measures

Name	Time	Method
Determine if the VEGF level correlates with tumor histology and behavior.	Every one to three months
Determine if the VEGF level is an indicator of the response to treatment.	Every one to three months
Determine if there is a relationship between VEGF level and outcome.	Every one to three months

Trial Locations

Locations (1)

Marquette General Hospital; 🇺🇸 Marquette, Michigan, United States